Published in BMC Microbiol on October 09, 2008
The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol (2011) 1.22
Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog (2009) 1.03
Metagenomics and novel gene discovery: promise and potential for novel therapeutics. Virulence (2013) 1.03
Proteomics and transcriptomics characterization of bile stress response in probiotic Lactobacillus rhamnosus GG. Mol Cell Proteomics (2010) 1.02
Allelic variation of bile salt hydrolase genes in Lactobacillus salivarius does not determine bile resistance levels. J Bacteriol (2009) 1.01
Specific osmolyte transporters mediate bile tolerance in Listeria monocytogenes. Infect Immun (2009) 1.01
Functional metagenomics reveals novel salt tolerance loci from the human gut microbiome. ISME J (2012) 0.97
Modulation of Lactobacillus plantarum gastrointestinal robustness by fermentation conditions enables identification of bacterial robustness markers. PLoS One (2012) 0.94
Rational design of improved pharmabiotics. J Biomed Biotechnol (2009) 0.91
How do bifidobacteria counteract environmental challenges? Mechanisms involved and physiological consequences. Genes Nutr (2011) 0.89
Treating critically ill patients with probiotics: Beneficial or dangerous? Gut Pathog (2011) 0.87
Enhancing the stress responses of probiotics for a lifestyle from gut to product and back again. Microb Cell Fact (2011) 0.86
Bifidobacteria-host interactions--an update on colonisation factors. Biomed Res Int (2014) 0.85
Probiotic therapy - recruiting old friends to fight new foes. Gut Pathog (2010) 0.84
A bile-inducible membrane protein mediates bifidobacterial bile resistance. Microb Biotechnol (2012) 0.83
Designer probiotics: Development and applications in gastrointestinal health. World J Gastrointest Pathophysiol (2015) 0.80
Under the microscope: From pathogens to probiotics and back. Bioengineered (2015) 0.78
Probiotics and pharmabiotics: alternative medicine or an evidence-based alternative? Bioeng Bugs (2009) 0.77
Harnessing bacteriocin biology as targeted therapy in the GI tract. Gut Microbes (2016) 0.75
Advances in the Microbiome: Applications to Clostridium difficile Infection. J Clin Med (2016) 0.75
Comparative genomics of Listeria species. Science (2001) 12.94
Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol (1996) 7.12
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 6.19
Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A (2007) 3.32
Assembly of the human intestinal microbiota. Trends Ecol Evol (2006) 3.21
Functional food science and gastrointestinal physiology and function. Br J Nutr (1998) 2.78
In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr (2001) 2.73
Extracellular replication of Listeria monocytogenes in the murine gall bladder. Science (2004) 2.58
Cloning and expression of the Lactococcus lactis subsp. cremoris SK11 gene encoding an extracellular serine proteinase. Gene (1989) 2.53
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.45
Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut (2003) 2.37
Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect Immun (2005) 1.90
Bile Acids: The Good, the Bad, and the Ugly. News Physiol Sci (1999) 1.81
A PrfA-regulated bile exclusion system (BilE) is a novel virulence factor in Listeria monocytogenes. Mol Microbiol (2005) 1.74
Gastrointestinal phase of Listeria monocytogenes infection. J Appl Microbiol (2005) 1.53
Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr (2001) 1.53
Insights into the taxonomy, genetics and physiology of bifidobacteria. Antonie Van Leeuwenhoek (2004) 1.43
Probiotic effects on inflammatory bowel disease. J Nutr (2007) 1.29
Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology (2007) 1.20
New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics-A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol (2005) 1.19
Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol (2006) 1.17
New frontiers in probiotic research. Lett Appl Microbiol (2007) 1.11
Biliary excretion as possible origin of Listeria monocytogenes in fecal carriers. Am J Vet Res (1992) 1.04
Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol (2006) 1.03
Differentiation of ingested and endogenous bifidobacteria by DNA fingerprinting demonstrates the survival of an unmodified strain in the gastrointestinal tract of humans. J Nutr (1997) 0.99
Mutations in the listerial proB gene leading to proline overproduction: effects on salt tolerance and murine infection. Appl Environ Microbiol (2001) 0.97
Investigation of protein export in Bifidobacterium breve UCC2003. Appl Environ Microbiol (2003) 0.96
Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog (2007) 0.95
Designer probiotics: a potential therapeutic for Clostridium difficile? J Med Microbiol (2008) 0.94
'Bioengineered Bugs' - a patho-biotechnology approach to probiotic research and applications. Med Hypotheses (2007) 0.92
Survival of lactococci during passage through mouse digestive tract. Can J Microbiol (2003) 0.91
The probiotic approach: an alternative treatment option in urology. Eur Urol (2005) 0.90
Engineered pharmabiotics with improved therapeutic potential. Hum Vaccin (2008) 0.83
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Bacteriocins: developing innate immunity for food. Nat Rev Microbiol (2005) 5.77
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
The interaction between bacteria and bile. FEMS Microbiol Rev (2005) 3.86
Surviving the acid test: responses of gram-positive bacteria to low pH. Microbiol Mol Biol Rev (2003) 3.54
Bacterial osmoadaptation: the role of osmolytes in bacterial stress and virulence. FEMS Microbiol Rev (2002) 3.40
Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A (2007) 3.32
Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol (2012) 2.76
Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A (2008) 2.53
The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol (2006) 2.53
'Big data', Hadoop and cloud computing in genomics. J Biomed Inform (2013) 2.40
Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci (2005) 2.21
Bile salt hydrolase activity in probiotics. Appl Environ Microbiol (2006) 2.19
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes. FEBS Lett (2004) 1.93
Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect Immun (2005) 1.90
Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A (2010) 1.89
Tools for functional postgenomic analysis of listeria monocytogenes. Appl Environ Microbiol (2008) 1.78
A PrfA-regulated bile exclusion system (BilE) is a novel virulence factor in Listeria monocytogenes. Mol Microbiol (2005) 1.74
Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol (2009) 1.68
Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence (2012) 1.63
The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol (2008) 1.62
Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry (2004) 1.61
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Bacteriocin production: a probiotic trait? Appl Environ Microbiol (2011) 1.57
Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol (2007) 1.54
Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage I Listeria monocytogenes. PLoS Pathog (2008) 1.53
Novel luciferase reporter system for in vitro and organ-specific monitoring of differential gene expression in Listeria monocytogenes. Appl Environ Microbiol (2006) 1.50
Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog (2011) 1.46
Bile stress response in Listeria monocytogenes LO28: adaptation, cross-protection, and identification of genetic loci involved in bile resistance. Appl Environ Microbiol (2002) 1.46
Multiple deletions of the osmolyte transporters BetL, Gbu, and OpuC of Listeria monocytogenes affect virulence and growth at high osmolarity. Appl Environ Microbiol (2002) 1.46
Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol (2006) 1.45
Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol (2011) 1.42
The LisRK signal transduction system determines the sensitivity of Listeria monocytogenes to nisin and cephalosporins. Antimicrob Agents Chemother (2002) 1.41
Accelerating in silico research with workflows: a lesson in Simplicity. Comput Biol Med (2013) 1.40
A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol (2007) 1.38
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Disruption of putative regulatory loci in Listeria monocytogenes demonstrates a significant role for Fur and PerR in virulence. Infect Immun (2004) 1.34
The CtsR regulator of Listeria monocytogenes contains a variant glycine repeat region that affects piezotolerance, stress resistance, motility and virulence. Mol Microbiol (2003) 1.33
Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol (2007) 1.33
Campylobacter ureolyticus: an emerging gastrointestinal pathogen? FEMS Immunol Med Microbiol (2010) 1.30
Isolation and analysis of bacteria with antimicrobial activities from the marine sponge Haliclona simulans collected from Irish waters. Mar Biotechnol (NY) (2008) 1.30
Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother (2005) 1.30
The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology (2009) 1.29
Discovery of medically significant lantibiotics. Curr Drug Discov Technol (2009) 1.29
AgrD-dependent quorum sensing affects biofilm formation, invasion, virulence and global gene expression profiles in Listeria monocytogenes. Mol Microbiol (2009) 1.29
M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol (2007) 1.27
A postgenomic appraisal of osmotolerance in Listeria monocytogenes. Appl Environ Microbiol (2003) 1.26
Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem (2007) 1.26
Molecular characterization of the arginine deiminase system in Listeria monocytogenes: regulation and role in acid tolerance. Environ Microbiol (2009) 1.26
Molecular and physiological analysis of the role of osmolyte transporters BetL, Gbu, and OpuC in growth of Listeria monocytogenes at low temperatures. Appl Environ Microbiol (2004) 1.24
Role for HtrA in stress induction and virulence potential in Listeria monocytogenes. Appl Environ Microbiol (2005) 1.24
Presence of GadD1 glutamate decarboxylase in selected Listeria monocytogenes strains is associated with an ability to grow at low pH. Appl Environ Microbiol (2005) 1.22
Lantibiotic immunity. Curr Protein Pept Sci (2008) 1.22
Contribution of penicillin-binding protein homologs to antibiotic resistance, cell morphology, and virulence of Listeria monocytogenes EGDe. Antimicrob Agents Chemother (2006) 1.21
Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett (2007) 1.21
Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci U S A (2005) 1.20
Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology (2007) 1.20
A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother (2009) 1.20
Relative ability of orally administered Lactobacillus murinus to predominate and persist in the porcine gastrointestinal tract. Appl Environ Microbiol (2004) 1.18
The dawning of a 'Golden era' in lantibiotic bioengineering. Mol Microbiol (2010) 1.18
Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol (2006) 1.17
The Dps-like protein Fri of Listeria monocytogenes promotes stress tolerance and intracellular multiplication in macrophage-like cells. Microbiology (2005) 1.17
Construction of p16Slux, a novel vector for improved bioluminescent labeling of gram-negative bacteria. Appl Environ Microbiol (2007) 1.17
Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology (2010) 1.16
Development of multiple strain competitive index assays for Listeria monocytogenes using pIMC; a new site-specific integrative vector. BMC Microbiol (2008) 1.16
The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol (2009) 1.16
Emerging dynamics of human campylobacteriosis in Southern Ireland. FEMS Immunol Med Microbiol (2011) 1.16
Molecular pathogenesis of Listeria monocytogenes in the alternative model host Galleria mellonella. Microbiology (2010) 1.16
Isoprenoid biosynthesis in bacterial pathogens. Microbiology (2012) 1.16